Voraussichtliches Ergebnis vor Steuern im Geschäftsjahr 2017
Veröffentlichung einer Kapitalmarktinformation
Mitteilung über Eigengeschäfte von Führungskräften gem. Art. 19 MAR
Veröffentlichung nach § 40 Abs. 1 WpHG
Einladung zur ordentlichen Hauptversammlung
Veränderungen im Vorstand
Mitteilung über Eigengeschäfte von Führungskräften gem. Art. 19 MAR
MELDUNG VOM 06.02.2017 20:30
Meldung drucken Artikel weiterleiten
Public disclosure of inside information according to article 17 MAR
Pressefach Pressefach

Biofrontera AG: Biofrontera Reports Positive Phase III Results for Ameluz® in Combination with Daylight-PDT

Leverkusen (pta031/06.02.2017/20:30) - Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, today received positive preliminary results for the primary endpoint of its Phase III clinical trial evaluating the safety and efficacy of its topical drug BF-200 ALA (Ameluz®) in combination with daylight photodynamic therapy (PDT). The study met its primary regulatory endpoint, demonstrating that Ameluz® in combination with daylight PDT was non-inferior (p<0.001) to standard of care MAL (Metvix®) for the treatment of mild to moderate actinic keratosis (AK), a superficial early skin cancer. These results will be employed for the filing of the EU label extension, which Biofrontera plans to submit in the second quarter of 2017. Detailed results for secondary endpoints will become available in the coming weeks.

The study met its primary endpoint, resulting after a single daylight PDT in 79.8% total lesion clearance rate per patient's side in the areas treated with BF-200 ALA and daylight PDT, compared to 76.5% total lesion clearance in areas treated with MAL and daylight PDT. For comparison, the much larger study ALA-AK-CT002, which compared the two products and demonstrated superiority of BF-200 ALA over MAL, resulted in lesion complete clearance rates after the first PDT with narrow-spectrum lamps of 77.1% with BF-200 ALA and 73.0% with MAL, respectively (1).

The intra-individual, randomized, observer-blind, multi-center study was performed with 52 patients at 7 centers in Spain and Germany. Every patient had 3 to 9 mild to moderate AK lesions in each of two comparable treatment areas on the face and/or scalp. For an intra-patient comparison of the treatments, each patient received daylight-PDT with BF-200 ALA on one side, and MAL on the other side. The study will be followed by assessments of lesion recurrence 6 and 12 months after daylight PDT.

BF-200 ALA is a topical prescription drug approved in the U.S. and EU (2,3). Daylight PDT offers a rather painless alternative to PDT with a specialized lamp, as the topical medication is activated by exposure to natural or artificial daylight.


The Management Board

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113, WKN: 604611

Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290


Aussender: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Ansprechpartner: Investor & public relations
Tel.: +49 (0) 214 87 63 20
ISIN(s): DE0006046113 (share)
Börsen: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
Biofrontera AG
23.03.2018 14:30
ADV-Rechtstag 2018: Die DSGVO ist da!
ADV Arbeitsgemeinschaft für Datenverarbeitung
23.03.2018 11:30
easyJet-Piloten mit Snapchat im Cockpit erwischt
23.03.2018 09:30
Erhaltungspflichten: Alles sicher rund ums Haus
Austrian Standards International - Standardisierung und Innovation
23.03.2018 06:05
Akademiker sind Mitmenschen gegenüber offener
22.03.2018 12:30
AOP Orphan and Bioprojet Pharma SAS entered a distribution agreement for Wakix®
AOP Orphan Pharmaceuticals Aktiengesellschaft
22.03.2018 12:30
AOP Orphan and Bioprojet Pharma SAS entered a distribution agreement for Wakix®
AOP Orphan Pharmaceuticals Aktiengesellschaft
Weitere News anzeigen